Melanoma patients and their families urged to speak up and put national spotlight on melanoma.
15 April 2021
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
Melanoma Institute Australia and Melanoma Patients Australia are partnering to develop the country’s first ever landmark melanoma report: State of the Nation – A Report into Melanoma.
This comprehensive report will examine the issues currently facing melanoma patients and carers across Australia and make recommendations for policy change and investment to substantially improve outcomes for them as well as the wider Australian community.
‘Australia has the highest melanoma rates in the world, and this State of the Nation report will for the first times provide an indepth assessment of the far-reaching impacts of the disease across the country,’ said Melanoma Institute Australia CEO Matthew Browne.
‘It will provide the opportunity to revolutionise melanoma policy, funding, care and support services going forward, which will in the long term benefit all Australians for generations to come.’
Critical to developing State of the Nation- A Report into Melanoma is input from melanoma patients and their carers from across Australia. This is a call to action and we are asking people to take part in an online survey so we can understand their personal experiences.
‘The survey will provide invaluable insights into the impact of melanoma and the realities faced by patients and their families,’ said Melanoma Patients Australia CEO Victoria Beedle.
‘Your feedback is critical to the success of this State of the Nation report and I urge all melanoma patients and their families to invest just half an hour in completing this survey. By doing so, you will become part of the solution to this huge problem impacting communities across the country.’
Key areas being addressed in State of the Nation- A Report into Melanoma include:
- melanoma prevention and awareness, including the effectiveness of current campaigns and what more needs to be done
- early detection and diagnosis including the feasibility of a national skin screening program
- treatment options available and access to breakthrough therapies
- supportive care services during and after treatment
- issues facing survivors and their families after successful treatment
- palliative and end of life care
- research priorities, opportunities and challenges.
The State of the Nation report will be presented to government mid-year with the aim of guiding future policy and funding direction to help reduce the impact of melanoma on Australian society.
‘Every 30 minutes another Australian is told they have melanoma – so in the time it takes you to do the survey, another family will be embarking on the daunting and frightening melanoma journey,’ Matthew Browne added.
‘Completing the survey is a small investment of time with a potentially life-changing impact, and I thank all our wonderful melanoma community for stepping up to help.’
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.
MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.
We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia.
This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.
A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients.